A Phase 2 interventional study of ISV 101 in Dry Eye Disease, sponsored by Sun Pharmaceutical Industries Limited. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-11-19.
Sponsored by Sun Pharmaceutical Industries Limited · Phase 2, Interventional, and Basic science
The purpose of this study is to evaluate the safety, tolerability, and efficacy in topical administration of differing dosing regimens of ISV-101 (Bromfenac in DuraSite® ophthalmic solution) compared to Vehicle and DuraSite alone.
1,292 studies on the registry are indexed under Dry Eye Syndromes; 191 are open to participants now.
Browse Dry Eye Syndromes studies →Sun Pharmaceutical Industries Limited is the lead sponsor of 58 studies on the registry; 5 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 22 (92%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: ISV 101
Drug: ISV 101
Drug: ISV 101
Drug: ISV 101
Drug: ISV 101
Bromfenac in DuraSite
Improvement in Corneal Fluorescein Staining
Time frame: Week 8
Improvement in OSDI Scoring
Time frame: Week 8
No study locations are listed for this record.
This study is withdrawn, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sun Pharmaceutical Industries Limited